$heff's $tation of $tocks & $olid DD

[$heff]

ONCS..$.30 DD post here. Strong catalysts in the 2nd half of the year with the first being the 8th World Congress of Melanoma (EADO). ONCS is scheduled to present updated Phase II Data in Melanoma on July 18th at 3pm in their Satellite Symposium session. Celgene will also be presenting at the same time.

52wk high is $.485 & 52wk low is $.145. This has a solid catalyst to move it higher with a specific date & timeframe with in the next 60 days. Previous positive results make a good case that the impending results in July could be positive.
Over the past month this has traded an avg of 995K shares in volume.

Roth Capital has placed a 12 month price target of $1 with a buy rating. Noble Financial has placed a price target of $2.

OncoSec Medical | Punit Dhillon 2013 Vision - YouTube http://bit.ly/15L0JLf

Oncosec Medical 2013 will be a year of crucial events.
http://seekingalpha.com/article/1049441-oncosec-medical-2013-will-be-a-year-of-crucial-events

Oncosec and the quest to develop a safe and effective IL-12 based treatment: http://bit.ly/10Wgjuv

World Melanoma Congress 2013.com: http://bit.ly/10KkIX9 Oncosec on Pg. 14 & pg 19

Major Catalysts in 2013

EADO Program on July 18

- July 18, 2013 — July 31, 2013 Present interim response data on Phase II melanoma program.
- July 18, 2013 — July 31, 2013 Present long-term PFS data from Phase I melanoma program.
- July 18, 2013 Present interim response data on Phase II Merkel cell carcinoma program.

- July 31, 2013 Complete enrolment for Phase II Merkel cell carcinoma program.
- August 31, 2013 End of Phase II Meeting with FDA for melanoma program.
- September 2013 Present interim data on cutaneous T-cell lymphoma program.
- October 15, 2013 Present final data for Phase II melanoma program.
- October 31, 2013 Present final data for Phase II Merkel cell carcinoma program.
- December 31, 2013 Launch Phase IIB melanoma program.